FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 169 filers reported holding FATE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 9.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,788 | -64.3% | 5,089 | -19.8% | 0.00% | – |
| Q2 2023 | $30,257 | -18.9% | 6,345 | -3.3% | 0.00% | – |
| Q1 2023 | $37,320 | -40.9% | 6,564 | +3.0% | 0.00% | – |
| Q4 2022 | $63,153 | +187.1% | 6,371 | +520.4% | 0.00% | – |
| Q3 2022 | $22,000 | +10.0% | 1,027 | +26.6% | 0.00% | – |
| Q2 2022 | $20,000 | -95.0% | 811 | -20.1% | 0.00% | -100.0% |
| Q1 2022 | $401,000 | +557.4% | 1,015 | +0.3% | 0.00% | – |
| Q4 2021 | $61,000 | -35.1% | 1,012 | -35.8% | 0.00% | – |
| Q3 2021 | $94,000 | -70.6% | 1,577 | -57.0% | 0.00% | -100.0% |
| Q2 2021 | $320,000 | +267.8% | 3,669 | +249.4% | 0.00% | – |
| Q1 2021 | $87,000 | -44.9% | 1,050 | -39.2% | 0.00% | – |
| Q4 2020 | $158,000 | -19.8% | 1,726 | -68.1% | 0.00% | -100.0% |
| Q3 2020 | $197,000 | +16.6% | 5,418 | +9.8% | 0.00% | 0.0% |
| Q2 2020 | $169,000 | +44.4% | 4,934 | +1.5% | 0.00% | – |
| Q1 2020 | $117,000 | – | 4,863 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
| Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
| Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
| Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
| DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
| Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
| Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
| Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
| ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |